Altachem Pharma Ltd.'s U.S. Patent Application allowed for HIV/AIDS drug
Tuesday September 30, 11:01 am ET
Trading Symbol: AAF:TSX Venture Exchange
EDMONTON, Sept. 30 /CNW/ - Mr. Warren Jackson, President and CEO of Altachem Pharma Ltd. is pleased to announce that Altachem's U.S. Patent Application, titled "Compounds with Anti-KS and Anti-HIV Activity" has been allowed by the United States Patent and Trademark Office for Altachem's proprietary drug ACP-HIP for treatment of HIV/AIDS.
"This patent recognizes and provides support for Altachem's integrated approach for the treatment of HIV/AIDS which confirms and adds to the value of the ACP-HIP technology which is programmed in Phase I Human Clinical Trials," states Mr. Jackson. Mr. Jackson also states, "This is the second U.S. Patent Application that has been allowed for Altachem's proprietary drugs this year. In February 2003, Altachem's U.S. Patent Application was allowed for its proprietary drug HB for the treatment of cancer. Altachem now has patents allowed in the U.S. for both of its lead products."
Altachem is continuing the approval process for the ACP-HIP patent application in other countries including Canada, China, Europe and Japan to further increase the value of this technology.
In addition to the two patents allowed for in the U.S., Altachem also has eight other pending patent applications. The Corporation will continue the approval process on these applications to further strengthen its patent portfolio, protect its proprietary technologies and increase the value of its drug development products.
ACP-HIP is a natural compound with potential activity against the causative viral agent of Kaposi's sarcoma. The Phase I Clinical Trial is primarily designed to evaluate the safety and tolerability of the compound, with ancillary studies designed to test efficacy of the compound in terms of tumor size, viral load, and effects on the immune system. The trial will involve patients that currently have Kaposi's sarcoma.
Altachem Pharma Ltd. is a publicly traded (TSX Venture Exchange: AAF - News), Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. The Corporation is developing a multi-tiered, integrated approach for the treatment of HIV/AIDS and cancer using non-toxic therapeutic products and adjunct therapies. The lead products of the Corporation are based on its two proprietary drugs: ACP- HIP and HB. The Corporation's manufacturing facilities located in Edmonton, Alberta and Shanghai, China are certified compliant with internationally recognized quality systems standards.
Certain information contained in this press release may be forward- looking and is subject to unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable.
"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein."
For further information
Roger Andrews, Investor Relations, Altachem Pharma Ltd., Tel.: (780) 486-8331 (Ext. 331), Toll-free: (877) 502-5939, Fax : (780) 448-1436, E-mail: roger@altachempharma.com, Web site: www.altachempharma.com
--------------------------------------------------------------------------------
Source: Altachem Pharma Ltd. |
